Ferring Pharmaceuticals Ltd

Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
Telephone: +44 (0)844 931 0050
Fax: +44 (0)844 931 0051
WWW: http://www.ferring.co.uk
Medical Information Direct Line: +44 (0)844 931 0054
Medical Information e-mail: medical@ferring.com
Medical Information Fax: +44 (0)844 931 0051

Summary of Product Characteristics last updated on the eMC: 24/06/2008
SPC DDAVP/Desmopressin Intranasal Solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 24/06/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   16-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

In section 4.8 (undesirable effects), disorders including aggression in children......has been added.
Updated on 04/07/2003 and displayed until 24/06/2008
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 10/06/2003 and displayed until 04/07/2003
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 19/09/2002 and displayed until 10/06/2003
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Updated on 08/08/2001 and displayed until 19/09/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 17/01/2001 and displayed until 08/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 17/01/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   desmopressin acetate